https://www.selleckchem.com/products/reversan.html
ptimize outcomes for patients with this illness. Immune checkpoint inhibitors have been approved for use as a second-line therapy for hepatocellular carcinoma (HCC) in patients who previously received sorafenib. Pembrolizumab has shown substantial antitumor activity and a favorable toxicity profile as a second-line treatment of HCC. However, considering the high cost of pembrolizumab, there is a need to assess its value by considering both the clinical efficacy and cost. To evaluate the cost-effectiveness of pembrolizumab vs placebo as
Like
Comment
Share
